Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of endogenous GIP in patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mechanisms in Endocrinology: FXR signalling - a novel target in metabolic diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hepatic microbiome in healthy lean and obese humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Expression of cholecystokinin and its receptors in the intestinal tract of type 2 diabetes patients and healthy controls

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objective: The insulinotropic effect of exogenous, intravenously infused glucose-dependent insulinotropic polypeptide (GIP) is impaired in patients with type 2 diabetes. We evaluated the effects of endogenous GIP in relation to glucose and bone metabolism in patients with type 2 diabetes using a selective GIP receptor antagonist and hypothesized that the effects of endogenous GIP were preserved.

Design: A randomized, double-blinded, placebo-controlled, crossover study.

Methods: Ten patients with overweight/obesity and type 2 diabetes (mean±s.d.; HbA1c 52 ± 11 mmol/mol; BMI 32.5 ± 4.8 kg/m2) were included. We infused a selective GIP receptor antagonist, GIP(3-30)NH2 (1200 pmol/kg/min), or placebo (saline) during two separate, 230-min, standardized, liquid mixed meal tests followed by a meal ad libitum. Subcutaneous adipose tissue biopsies were analyzed.

Results: Compared with placebo, GIP(3-30)NH2 reduced postprandial insulin secretion (Δbaseline-subtracted area under the curve (bsAUC)C-peptide% ± s.e.m.; -14 ± 6%, P = 0.021) and peak glucagon (Δ% ± s.e.m.; -11 ± 6%, P = 0.046) but had no effect on plasma glucose (P = 0.692). Suppression of bone resorption (assessed by circulating carboxy-terminal collagen crosslinks (CTX)) was impaired during GIP(3-30)NH2 infusion compared with placebo (ΔbsAUCCTX; ±s.e.m.; -4.9 ± 2 ng/mL × min, P = 0.005) corresponding to a ~50% reduction. Compared with placebo, GIP(3-30)NH2 did not affect plasma lipids, meal consumption ad libitum or adipose tissue triglyceride content.

Conclusions: Using a selective GIP receptor antagonist during a meal, we show that endogenous GIP increases postprandial insulin secretion with little effect on postprandial glycaemia but is important for postprandial bone homeostasis in patients with type 2 diabetes.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume185
Issue number1
Pages (from-to)33-45
Number of pages13
ISSN0804-4643
DOIs
Publication statusPublished - 21 May 2021

    Research areas

  • Adult, Aged, Blood Glucose/drug effects, Bone Resorption/metabolism, Collagen Type I/drug effects, Cross-Over Studies, Diabetes Mellitus, Type 2/metabolism, Double-Blind Method, Feeding Behavior/drug effects, Gastric Inhibitory Polypeptide/metabolism, Humans, Insulin Secretion/drug effects, Male, Middle Aged, Obesity/metabolism, Peptide Fragments/pharmacology, Peptides/drug effects, Postprandial Period, Random Allocation, Receptors, Gastrointestinal Hormone/antagonists & inhibitors, Subcutaneous Fat/drug effects, Triglycerides/metabolism

ID: 65747238